Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: AVITA Medical, Inc. ("Company")
ARBN: 641 288 155

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Professor Suzanne Crowe
Date of last notice	29 January 2026

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	3 June 2026 (United States) / 4 June 2026 (Australia)
No. of securities held prior to change	22,990 CDIs 42,336 Common Stock 2,550 Options expiring 23 Dec 2031 ex USD $12.18 5,395 Options expiring 13 Dec 2032 ex USD $6.95 2,646 Options expiring 7 June 2033 ex USD $14.17 3,943 Options expiring 6 June 2034, ex USD $9.51 4,295 Options expiring 22 January 2035, ex USD $8.73

+ See chapter 19 for defined terms.

Class	a) unquoted restricted stock units in the Company to acquire shares of common stock of the Company (which may be represented by CDIs) ("RSUs") b) Options expiring 21 January 2036 ex USD $3.77
Number acquired	a) 22,214 RSUs b) 16,133 Options expiring 21 January 2036 ex USD $3.77
Number disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	22,990 CDIs 42,336 Common Stock 22,214 RSUs 2,550 Options expiring 23 Dec 2031 ex USD $12.18 5,395 Options expiring 13 Dec 2032 ex USD $6.95 2,646 Options expiring 7 June 2033 ex USD $14.17 3,943 Options expiring 6 June 2034, ex USD $9.51 4,295 Options expiring 22 January 2035, ex USD $8.73 16,133 Options expiring 21 January 2036 ex USD $3.77
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of RSUs and Options as approved by stockholders at 2026 ASM

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A

Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: AVITA Medical, Inc. ("Company")
ARBN: 641 288 155

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Jeremy Curnock Cook
Date of last notice	29 January 2026

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	3 June 2026 (United States) / 4 June 2026 (Australia)
No. of securities held prior to change	39,836 Common Stock (which may be represented by CDIs) 2,550 Options expiring 23 Dec 2031 ex USD $12.18 5,395 Options expiring 13 Dec 2032 ex USD $6.95 2,646 Options expiring 7 June 2033 ex USD $14.17 3,943 Options expiring 6 June 2034, ex USD $9.51 4,295 Options expiring 22 January 2035, ex USD $8.73

+ See chapter 19 for defined terms.

Class	a) unquoted restricted stock units in the Company to acquire shares of common stock of the Company (which may be represented by CDIs) ("RSUs") b) Options expiring 21 January 2036 ex USD $3.77
Number acquired	a) 22,214 RSUs b) 16,133 Options expiring 21 January 2036 ex USD $3.77
Number disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	39,836 Common Stock 22,214 RSUs 2,550 Options expiring 23 Dec 2031 ex USD $12.18 5,395 Options expiring 13 Dec 2032 ex USD $6.95 2,646 Options expiring 7 June 2033 ex USD $14.17 3,943 Options expiring 6 June 2034, ex USD $9.51 4,295 Options expiring 22 January 2035, ex USD $8.73 16,133 Options expiring 21 January 2036 ex USD $3.77
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of RSUs and Options as approved by stockholders at 2026 ASM

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A

Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: AVITA Medical, Inc. ("Company")
ARBN: 641 288 155

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Robert McNamara
Date of last notice	29 January 2026

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	a) 3 June 2026 (United States) / 4 June 2026 (Australia) b) 6 June 2026 (US) / 7 June 2026 (Australia)
No. of securities held prior to change	83,313 Common Stock (which may be represented by CDIs) 3,458 unquoted restricted stock units in the Company to acquire shares of common stock of the Company (which may be represented by CDIs) ("RSUs") 7,092 Options expiring 7 June 2033, ex USD $14.17 3,943 Options expiring 6 June 2034, ex USD $9.51 4,295 Options expiring 22 January 2035, ex USD $8.73

+ See chapter 19 for defined terms.

Class	a) Common Stock b) RSUs c) Options expiring 21 January 2036 ex USD $3.77
Number acquired	a) 3,458 Common Stock b) 22,214 RSUs c) 16,133 expiring 21 January 2036 ex USD $3.77
Number disposed	3,458 RSUs
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	86,771 Common Stock 22,214 RSUs 7,092 Options expiring 7 June 2033, ex USD $14.17 3,943 Options expiring 6 June 2034, ex USD $9.51 4,295 Options expiring 22 January 2035, ex USD $8.73 16,133 Options expiring 21 January 2036 ex USD $3.77
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of RSUs and Options as approved by stockholders at 2026 ASM Acquisition of Common Stock upon conversion of RSUs

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A

No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: AVITA Medical, Inc. ("Company")
ARBN: 641 288 155

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Jan Stern Reed
Date of last notice	29 January 2026

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	3 June 2026 (United States) / 4 June 2026 (Australia)

No. of securities held prior to change	48,120 Common Stock (which may be represented by CDIs) 2,891 unquoted restricted stock units in the Company to acquire shares of common stock of the Company (which may be represented by CDIs) ("RSUs") 7,475 Options expiring 23 Dec 2031 ex USD $12.18 5,395 Options expiring 13 Dec 2032 ex USD $6.95 2,646 Options expiring 7 June 2033 ex USD $14.17 3,943 Options expiring 6 June 2034, ex USD $9.51 4,295 Options expiring 22 January 2035, ex USD $8.73
Class	a) RSUs b) Options expiring 21 January 2036 ex USD $3.77
Number acquired	a) 22,214 RSUs b) 16,133 Options expiring 21 January 2036 ex USD $3.77
Number disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil

+ See chapter 19 for defined terms.

No. of securities held after change	48,120 Common Stock 25,105 RSUs 7,475 Options expiring 23 Dec 2031 ex USD $12.18 5,395 Options expiring 13 Dec 2032 ex USD $6.95 2,646 Options expiring 7 June 2033 ex USD $14.17 3,943 Options expiring 6 June 2034, ex USD $9.51 4,295 Options expiring 22 January 2035, ex USD $8.73 16,133 Options expiring 21 January 2036 ex USD $3.77
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of RSUs and Options as approved by stockholders at 2026 ASM

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A

Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: AVITA Medical, Inc. ("Company")
ARBN: 641 288 155

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr. Michael Tarnoff
Date of last notice	7 August 2025

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	3 June 2026 (United States) / 4 June 2026 (Australia)
No. of securities held prior to change	Nil
Class	a) unquoted restricted stock units in the Company to acquire shares of common stock of the Company (which may be represented by CDIs) ("RSUs") b) Options expiring 6 August 2035 ex USD $5.36 c) Options expiring 21 January 2036 ex USD $3.77

+ See chapter 19 for defined terms.

Number acquired	a) 48,464 RSUs b) 19,063 Options expiring 6 August 2035 ex USD $5.36 c) 16,133 Options expiring 21 January 2036 ex USD $3.77
Number disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	48,464 RSUs 19,063 Options expiring 6 August 2035 ex USD $5.36 16,133 Options expiring 21 January 2036 ex USD $3.77
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of RSUs and Options as approved by stockholders at 2026 ASM

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder **(if issued securities)**	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A

+ See chapter 19 for defined terms.

Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: AVITA Medical, Inc. ("Company")
ARBN: 641 288 155

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Cary G. Vance
Date of last notice	3 June 2026

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	6 June 2026 (US) / 7 June 2026 (Australia)
No. of securities held prior to change	37,313 Common Stock (which may be represented by CDIs) 3,458 unquoted restricted stock units in the Company to acquire shares of common stock of the Company (which may be represented by CDIs) ("RSUs") 7,092 Options expiring 7 June 2033, ex USD $14.17 3,943 Options expiring 6 June 2034, ex USD $9.51 4,295 Options expiring 22 January 2035, ex USD $8.73
Class	Common Stock RSUs

Number acquired	3,458 Common Stock
Number disposed	3,458 RSUs
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	40,771 Common Stock 7,092 Options expiring 7 June 2033, ex USD $14.17 3,943 Options expiring 6 June 2034, ex USD $9.51 4,295 Options expiring 22 January 2035, ex USD $8.73
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Acquisition of Common Stock upon conversion of RSUs

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder **(if issued securities)**	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: AVITA Medical, Inc. ("Company")
ARBN: 641 288 155

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Joseph Woody
Date of last notice	4 June 2026

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	3 June 2026 (US) / 4 June 2026 (Australia)
No. of securities held prior to change	20,000 Common Stock
Class	a) Common Stock (which may be represented by CDIs) b) unquoted restricted stock units in the Company to acquire shares of common stock of the Company (which may be represented by CDIs) ("RSUs") c) Options expiring 5 January 2036 ex USD $3.47 d) Options expiring 21 January 2036 ex USD $3.77

Number acquired	a) 25,200 Common Stock b) 62,761 RSUs c) 29,446 Options expiring 5 January 2036 ex USD $3.47 d) 16,133 Options expiring 21 January 2036 ex USD $3.77
Number disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	a) $103,649 b) Nil c) Nil d) Nil
No. of securities held after change	45,200 Common Stock 62,761 RSUs 29,446 Options expiring 5 January 2036 ex USD $3.47 16,133 Options expiring 21 January 2036 ex USD $3.77
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	a) Purchased on the NASDAQ Stock Market b) c) & d) Issue of RSUs and Options as approved by stockholders at 2026 ASM

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A

Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.